This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
The #1 prescribed oral anticoagulant among cardiologists for stroke risk reduction in patients
with NVAF1*
The #1 prescribed oral anticoagulant among cardiologists for stroke risk reduction in patients
with NVAF1*
*Based on SHA (PHAST) Total Prescription Database (TRx). Oral anticoagulant prescriptions were written by cardiologists and filled by patients. Claims valid as of 7/16/21.
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with NVAF. ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial therapy.
Download guides to help your patients getting started on treatment, dosing guides, coverage support, and more.
Our live specialists are just a phone call away and ready to help you and your patients.
1-855-ELIQUIS (354-7847)
Monday–Friday, 8 AM–8 PM ET
Get the information you and your patients need when considering ELIQUIS, including clinical data, access support, and what to expect during treatment.
Help eligible patients get started on ELIQUIS with a 30-day trial and $10
co-pay.†
†Eligibility requirements and terms of use apply.
Help eligible patients get started on ELIQUIS with a 30-day trial and $10 co-pay.†
†Eligibility requirements and terms of use apply.
Reference:
1. Data on File: ELQ Market Share. Bristol-Myers Squibb Company, Princeton, NJ.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.